Currently out of the existing stock ratings of Kyle Boucher, 5 are a BUY (62.5%), 3 are a HOLD (37.5%).

Kyle Boucher

Work Performance Price Targets & Ratings Chart

Analyst Kyle Boucher, currently employed at TD COWEN, has had 63.33% of price targets met with an average potential upside of 29.49%, reached in 55 days on average.

Kyle Boucher has documented 16 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MYGN, Myriad Genetics at 05-Nov-2026.

Wall Street Analyst Kyle Boucher

Analyst best performing recommendations are on TECH (BIO-TECHNE CORP).
The best stock recommendation documented was for TECH (BIO-TECHNE CORP) on 6/23/2026. The price target of $65 was fulfilled within 2 days with a profit of $8.86 (15.78%), with a performance score of 78.91.

Average potential price target upside

LAB Standard Biotools TECH Bio-Techne Corp MYGN Myriad Genetics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 13-Aug-2025

$2.5

1 years 3 months 3 days ago
(13-Aug-2025)

1/5 (20%)

$0.54 (27.55%)

4

Hold Since 27-Feb-2025

$4

1 years 8 months 20 days ago
(27-Feb-2025)

1/2 (50%)

$1.63 (68.78%)

93

Buy Since 13-Mar-2019

$10

$12

4 years 11 months ago
(16-Dec-2021)

0/5 (0%)

$6.21 (163.85%)

Buy Since 07-Aug-2020

$7

$8

5 years 6 months 4 days ago
(12-May-2021)

1/5 (20%)

$1.82 (35.14%)

77

Buy Since 02-Nov-2018

$9

$14

6 years 9 months 5 days ago
(11-Feb-2020)

3/9 (33.33%)

$5.22 (138.10%)

103

Show more analysts

Please expand the browser size to see the chart

Which stock is Kyle Boucher most bullish on?

Potential upside of $1.09 has been obtained for MYGN (MYRIAD GENETICS)

Which stock is Kyle Boucher most reserved on?

Potential downside of $0.2 has been obtained for TECH (BIO-TECHNE CORP)

What Year was the first public recommendation made by Kyle Boucher?

On 2025
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?